Serotonin and Cardiovascular Diseases

References (168)

1. References
2. Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013). The concise guide to pharmacology 2013/14: G protein-coupled receptors. Br J Pharmacol, 170, 1459-1581.
3. Amireault, P., & Dube, F. (2005). Intracellular cAMP and calcium signaling by serotonin in mouse cumulus-oocyte complexes. Mol Pharmacol, 68, 1678-1687.
4. Antonini, A., & Poewe, W. (2007). Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol, 6, 826-829.
5. Arinami, T., Ohtsuki, T., Yamakawa-Kobayashi, K., Amemiya, H., Fujiwara, H., Kawata, K., Ishiguro, H., & Hamaguchi, H. (1999). A synergistic effect of serotonin transporter gene polymorphism and smoking in association with CHD. Thromb Haemost, 81, 853- 856.
6. Ayme-Dietrich, E., Lawson, R., Côté, F., de Tapia, C., Da Silva, S., Ebel, C., Hechler, B., Gachet, C., Guyonnet, J., Rouillard, H., Stoltz, J., Quentin, E., Banas, S., Daubeuf, F., Frossard, N., Gasser, B., Mazzucotelli, J., Hermine, O., Maroteaux, L., & Monassier, L. (2017). Serotonergic 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors. Br J Pharmacol, 174, 4123-4141.
7. Ayme-Dietrich, E., Lawson, R., Gasser, B., Dallemand, R., Bischoff, N., & Monassier, L. (2012). Mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy. Fundam Clin Pharmacol, 26, 215-218.
8. Ayme-Dietrich, E., Marzak, H., Lawson, R., Mokni, W., Wendling, O., Combe, R., Becker, J., El Fertak, L., Champy, M., Matz, R. L., Andriantsitohaina, R., Doly, S., Boutourlinsky, K., Maroteaux, L., & Monassier, L. (2015). Contribution of serotonin to cardiac remodeling associated with hypertensive diastolic ventricular dysfunction in rats. J Hypertens, 33, 2310-2321.
9. Bach, T., Syversveen, T., Kvingedal, A. M., Krobert, K. A., Brattelid, T., Kaumann, A. J., & Levy, F. O. (2001). 5-HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn-Schmied Arch Pharmacol, 363, 146-160.
10. Bai, C.-F., Liu, J.-C., Zhao, R., Cao, W., Liu, S.-B., Zhang, X.-N., Guo, H.-J., Yang, Q., Yi, D.-H., & Zhao, M.-G. (2010). Role of 5-HT2B receptor in cardiomyocyte apoptosis of norepinephrine-induced cardiomyopathy model in rats. Clin Exp Pharmacol Physiol, 37, e145-e151.
11. Banes, A. K., Loberg, R. D., Brosius, F. C., 3rd, & Watts, S. W. (2001). Inability of serotonin to activate the c-Jun N-terminal kinase and p38 kinase pathways in rat aortic vascular smooth muscle cells. BMC Pharmacol, 1, 8.
12. Birkeland, J. A. K., Sjaastad, I., Brattelid, T., Qvigstad, E., Moberg, E. R., Krobert, K. A., Bjørnerheim, R., Skomedal, T., Sejersted, O. M., Osnes, J.-B., & Levy, F. O. (2007). Effects of treatment with a 5-HT4 receptor antagonist in heart failure. Br J Pharmacol, 150, 143-152.
13. Blasco-Fontecilla, H., Baca-Garcia, E., & de Leon, J. (2010). Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade. Schizophr Res, 119, 160-163.
14. Brattelid, T., Qvigstad, E., Birkeland, J. A., Swift, F., Bekkevold, S. V., Krobert, K. A., Sejersted, O. M., Skomedal, T., Osnes, J. B., Levy, F. O., & Sjaastad, I. (2007). Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle. J Mol Cell Cardiol, 43, 767- 779.
15. Brattelid, T., Qvigstad, E., Lynham, J. A., Molenaar, P., Aass, H., Geiran, O., Skomedal, T., Osnes, J. B., Levy, F. O., & Kaumann, A. J. (2004). Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn-Schmied Arch Pharmacol, 370, 157-166.
16. Brattelid, T., Qvigstad, E., Moltzau, L. R., Bekkevold, S. V. S., Sandnes, D. L., Birkeland, J. A. K., Skomedal, T., Osnes, J.-B., Sjaastad, I., & Levy, F. O. (2012). The cardiac ventricular 5-HT4 receptor is functional in late foetal development and is reactivated in heart failure. PloS one, 7, e45489.
17. Buzzi, M. G., Carter, W. B., Shimizu, T., Heath, H. d., & Moskowitz, M. A. (1991). Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology, 30, 1193-1200.
18. Castanheira, J., Valente-Dos-Santos, J., Costa, D., Martinho, D., Fernandes, J., Duarte, J., Sousa, N., Vaz, V., Rama, L., Figueiredo, A., & Coelho-E-Silva, M. (2017). Cardiac remodeling indicators in adolescent athletes. Revista da Associacao Medica Brasileira (1992), 63, 427-434.
19. Castro, L., Mialet-Perez, J., Guillemeau, A., Stillitano, F., Zolk, O., Eschenhagen, T., Lezoualc'h, F., Bochet, P., & Fischmeister, R. (2005). Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes. J Mol Cell Cardiol, 39, 335-344.
20. Chambers, C. D., Hernandez-Diaz, S., Van Marter, L. J., Werler, M. M., Louik, C., Jones, K. L., & Mitchell, A. A. (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med, 354, 579-587.
21. Chan, S. Y., & Loscalzo, J. (2008). Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol, 44, 14-30.
22. Chandra, M., Gupta, V., Johri, A. K., Misra, R., Kumar, A., Gujrati, V., & Shanker, K. (1994). Serotonergic mechanisms in heart failure. Indian Heart J, 46, 153-156.
23. Chang Chien, C.-C., Hsin, L.-W., & Su, M.-J. (2015). Activation of serotonin 5-HT₇ receptor induces coronary flow increase in isolated rat heart. Eur J Pharmacol, 748, 68-75.
24. Chen, Y. X., Wang, W. D., Song, X. J., Gu, Y. Q., Tian, H. Y., Hu, H. J., Zhao, J. C., Li, X. Q., & Liu, C. W. (2015). Prospective randomized study of Sarpogrelate versus Clopidogrel-based dual antiplatelet therapies in patients undergoing femoropopliteal arterial endovascular interventions: preliminary results. Chin Med J (Engl), 128, 1563- 1566.
25. Choi, D.-S., Ward, S., Messaddeq, N., Launay, J.-M., & Maroteaux, L. (1997). 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. Development, 124, 1745-1755.
26. Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997). Valvular heart disease associated with fenfluramine- phentermine. N Engl J Med, 337, 581-588.
27. Corominas, R., Sobrido, M. J., Ribasés, M., Cuenca-León, E., Blanco-Arias, P., Narberhaus, B., Roig, M., Leira, R., López-González, J., Macaya, A., & Cormand, B. (2010). Association study of the serotoninergic system in migraine in the Spanish population. Am J Med Genet B, 153B, 177-184.
28. Cote, F., Fligny, C., Bayard, E., Launay, J. M., Gershon, M. D., Mallet, J., & Vodjdani, G. (2007). Maternal serotonin is crucial for murine embryonic development. Proc Natl Acad Sci U S A, 104, 329-334.
29. Coto, E., Reguero, J. R., Alvarez, V., Morales, B., Batalla, A., Gonzalez, P., Martin, M., Garcia-Castro, M., Iglesias-Cubero, G., & Cortina, A. (2003). 5-Hydroxytryptamine 5- HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clin Sci (Lond), 104, 241-245.
30. Deraet, M., Manivet, P., Janoshazi, A., Callebert, J., Guenther, S., Drouet, L., Launay, J. M., & Maroteaux, L. (2005). The natural mutation encoding a C terminus-truncated 5- Hydroxytryptamine2B receptor is a gain of proliferative functions. Mol Pharmacol, 67, 983-991.
31. Doggrell, S. A. (2004). Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin Investig Drugs, 13, 865-874.
32. Droogmans, S., Cosyns, B., D'Haenen, H., Creeten, E., Weytjens, C., Franken, P. R., Scott, B., Schoors, D., Kemdem, A., Close, L., Vandenbossche, J. L., Bechet, S., & Van Camp, G. (2007a). Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol, 100, 1442-1445.
33. Droogmans, S., Franken, P. R., Garbar, C., Weytjens, C., Cosyns, B., Lahoutte, T., Caveliers, V., Pipeleers-Marichal, M., Bossuyt, A., Schoors, D., & Van Camp, G. (2007b). In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J, 28, 2156-2162.
34. Dumitrascu, R., Kulcke, C., Königshoff, M., Kouri, F., Yang, X., Morrell, N., Ghofrani, H. A., Weissmann, N., Reiter, R., Seeger, W., Grimminger, F., Eickelberg, O., Schermuly, R. T., & Pullamsetti, S. S. (2011). Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J, 37, 1104-1118.
35. Elangbam, C. S. (2010). Drug-induced valvulopathy: an update. Toxicol Pathol, 38, 837-848.
36. Elangbam, C. S., Job, L. E., Zadrozny, L. M., Barton, J. C., Yoon, L. W., Gates, L. D., & Slocum, N. (2008). 5-hydroxytryptamine (5-HT)-induced valvulopathy: compositional valvular alterations are associated with 5-HT2B receptor and 5-HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol, 60, 253-262.
37. Elangbam, C. S., Lightfoot, R. M., Yoon, L. W., Creech, D. R., Geske, R. S., Crumbley, C. W., Gates, L. D., & Wall, H. G. (2005). 5-Hydroxytryptamine (5-HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats. J Histochem Cytochem, 53, 671-677.
38. Ferrans, V. J., & Roberts, W. C. (1976). The carcinoid endocardial plaque; an ultrastructural study. Hum Pathol, 7, 387-409.
39. Ferrari, M. D. (1998). Migraine. Lancet, 351, 1043-1051.
40. Fitzgerald, L. W., Burn, T. C., Brown, B. S., Patterson, J. P., Corjay, M. H., Valentine, P. A., Sun, J.-H., Link, J. R., Abbaszade, I., Hollis, J. M., Largent, B. L., Hartig, P. R., Hollis, G. F., Meunier, P. C., Robichaud, A. J., & Robertson, D. W. (2000). Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol, 57, 75-81.
41. Fox, D. J., & Khattar, R. S. (2004). Carcinoid heart disease: presentation, diagnosis, and management. Heart, 90, 1224-1228.
42. Fox, S. H. (2014). Pimavanserin as treatment for Parkinson's disease psychosis. Lancet, 383, 494-496.
43. Fujita, M., Minamino, T., Sanada, S., Asanuma, H., Hirata, A., Ogita, H., Okada, K., Tsukamoto, O., Takashima, S., Tomoike, H., Node, K., Hori, M., & Kitakaze, M. (2004). Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. J Mol Cell Cardiol, 37, 1219-1223.
44. Fumeron, F., Betoulle, D., Nicaud, V., Evans, A., Kee, F., Ruidavets, J. B., Arveiler, D., Luc, G., & Cambien, F. (2002). Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Temoins de l'Infarctus du Myocarde (ECTIM). Circulation, 105, 2943-2945.
45. Gaddum, J. H., & Picarelli, Z. P. (1957). Two kinds of tryptamine receptors. Br J Pharmacol, 12, 323-328.
46. Garcia-Pedraza, J. A., Garcia, M., Martin, M. L., San Roman, L., & Moran, A. (2014). The role of endothelium-derived hyperpolarizing factor and cyclooxygenase pathways in the inhibitory serotonergic response to the pressor effect elicited by sympathetic stimulation in chronic sarpogrelate treated rats. Eur J Pharmacol, 731, 80-87.
47. Gelernter, J., Cubells, J. F., Kidd, J. R., Pakstis, A. J., & Kidd, K. K. (1999). Population studies of polymorphisms of the serotonin transporter protein gene. Am J Med Genet, 88, 61-66.
48. Goadsby, P. J., Lipton, R. B., & Ferrari, M. D. (2002). Migraine-current understanding and treatment. N Engl J Med, 346, 257-270.
49. Goichot, B., Grunenberger, F., Trinh, A., Mazzucotelli, J. P., Weber, J. C., Vinzio, S., & Schlienger, J. L. (2005). [Carcinoid heart disease: an underestimated complication of endocrine digestive tumors].
50. Gastroenterol Clin Biol, 29, 997-1000.
51. Gustafsson, B. I., Tommeras, K., Nordrum, I., Loennechen, J. P., Brunsvik, A., Solligard, E., Fossmark, R., Bakke, I., Syversen, U., & Waldum, H. (2005). Long-term serotonin administration induces heart valve disease in rats. Circulation, 111, 1517-1522.
52. Hanna, G. L., Himle, J. A., Curtis, G. C., Koram, D. Q., Veenstra-VanderWeele, J., Leventhal, B. L., & Cook, E. H., Jr. (1998). Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology, 18, 102-111.
53. Hart, E. A., Meijs, T. A., Meijer, R. C. A., Dreijerink, K. M., Tesselaar, M. E., de Groot, C. A., Valk, G. D., & Chamuleau, S. A. J. (2017). Carcinoid heart disease: a guide for screening and timing of surgical intervention. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 25, 471-478.
54. Hayashi, T., Sumi, D., Matsui-Hirai, H., Fukatsu, A., Arockia Rani, P. J., Kano, H., Tsunekawa, T., & Iguchi, A. (2003). Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis, 168, 23-31.
55. Heils, A., Teufel, A., Petri, S., Stober, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996). Allelic variation of human serotonin transporter gene expression. J Neurochem, 66, 2621-2624.
56. Hendrikx, M., Van Dorpe, J., Flameng, W., & Daenen, W. (1996). Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis, 5, 235-237.
57. Hergovich, N., Aigner, M., Eichler, H. G., Entlicher, J., Drucker, C., & Jilma, B. (2000). Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther, 68, 435-442.
58. Hervé, P., Launay, J. M., Scrobohaci, M. L., Brenot, F., Simonneau, G., Petitpretz, P., Poubeau, P., Cerrina, J., Duroux, P., & Drouet, L. (1995). Increased plasma serotonin in primary pulmonary hypertension. Am J Med, 99, 249-254.
59. Horvath, J., Fross, R. D., Kleiner-Fisman, G., Lerch, R., Stalder, H., Liaudat, S., Raskoff, W. J., Flachsbart, K. D., Rakowski, H., Pache, J. C., Burkhard, P. R., & Lang, A. E. (2004). Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord, 19, 656-662.
60. Hoskin, K. L., Kaube, H., & Goadsby, P. J. (1996). Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain, 119, 249-256.
61. Hossain, M., Muntasir, H. A., Ishiguro, M., Bhuiyan, M. A., Rashid, M., Sugihara, T., & Nagatomo, T. (2012). Mechanism of inverse agonist action of sarpogrelate at the constitutively active mutant of human 5-HT2A receptor revealed by molecular modeling. Biol Pharm Bull, 35, 1553-1559.
62. Iizuka, K., Hamaue, N., Machida, T., Hirafuji, M., & Tsuji, M. (2009). Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res, 34, 18-30.
63. Ishida, T., Kawashima, S., Hirata, K., & Yokoyama, M. (1998). Nitric oxide is produced via 5-HT1B and 5-HT2B receptor activation in human coronary artery endothelial cells. Kobe J Med Sci, 44, 51-63.
64. Iwabayashi, M., Taniyama, Y., Sanada, F., Azuma, J., Iekushi, K., Kusunoki, H., Chatterjee, A., Okayama, K., Rakugi, H., & Morishita, R. (2012). Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5- HT1B/Akt/eNOS pathway in diabetic mice. Atherosclerosis, 220, 337-342.
65. Jaffre, F., Bonnin, P., Callebert, J., Debbabi, H., Setola, V., Doly, S., Monassier, L., Mettauer, B., Blaxall, B. C., Launay, J. M., & Maroteaux, L. (2009). Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res, 104, 113-123.
66. Jaffré, F., Callebert, J., Sarre, A., Etienne, N., Nebigil, C. G., Launay, J. M., Maroteaux, L., & Monassier, L. (2004). Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1 beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation, 110, 969-974.
67. Jahnichen, S., Horowski, R., & Pertz, H. H. (2005). Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol, 513, 225-228.
68. Janeway, T. C., Richadson, H. B., & Park, E. A. (1918). Experiments on the vasoconstrictor action of blood serum. Arch. Int. Med., 21, 565-603.
69. Jian, B., Xu, J., Connolly, J., Savani, R. C., Narula, N., Liang, B., & Levy, R. J. (2002). Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol, 161, 2111-2121.
70. Johnson, K. W., Nelson, D. L., Dieckman, D. K., Wainscott, D. B., Lucaites, V. L., Audia, J. E., Owton, W. M., & Phebus, L. A. (2003). Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation. Cephalalgia, 23, 117-123.
71. Joynt, K. E., & O'Connor, C. M. (2005). Lessons from SADHART, ENRICHD, and other trials. Psychosom Med, 67 Suppl 1, S63-66.
72. Kalkman, H. O. (1994). Is migraine prophylactic activity caused by 5-HT2B or 5-HT2C receptor blockade? Life Sci., 54, 641-644.
73. Kamel, R., Garcia, S., Lezoualc'h, F., Fischmeister, R., Muller, S., Hoebek, J., & Eftekhari, P. (2007). Immunomodulation by maternal autoantibodies of the fetal serotoninergic 5- HT4 receptor and its consequences in early BALB/c mouse embryonic development. BMC Dev Biol, 7, 34.
74. Kaumann, A. J., & Levy, F. O. (2006). Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium. Br J Pharmacol, 147, 128-130.
75. Kawamura, M., Ishiguro, M., Nagamine, T., & Houkin, K. (2013). Sarpogrelate dilates cerebral arteries in the absence of exogenous serotonin. Neurol Med Chir (Tokyo), 53, 291-298.
76. Kéreveur, A., Callebert, J., Humbert, M., Hervé, P., Simonneau, G., Launay, J. M., & Drouet, L. (2000). High plasma serotonin levels in primary pulmonary hypertension : effect of long-term epoprostenol (Prostacyclin) therapy. Arterioscler Thromb Vasc Biol, 20, 2233-2239.
77. Kjekshus, J. K., Torp-Pedersen, C., Gullestad, L., Kober, L., Edvardsen, T., Olsen, I. C., Sjaastad, I., Qvigstad, E., Skomedal, T., Osnes, J. B., & Levy, F. O. (2009). Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur J Heart Fail, 11, 771-778.
78. Klein, D., Demory, A., Peyre, F., Kroll, J., Géraud, C., Ohnesorge, N., Schledzewski, K., Arnold, B., & Goerdt, S. (2009). Wnt2 acts as an angiogenic growth factor for non- sinusoidal endothelial cells and inhibits expression of stanniocalcin-1. Angiogenesis, 12, 251-265.
79. Kodama, A., Komori, K., Hattori, K., Yamanouchi, D., Kajikuri, J., & Itoh, T. (2009). Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft. J Vasc Surg, 49, 1272-1281.
80. Kokubu, N., Tsuchihashi, K., Yuda, S., Hase, M., Eguchi, M., Wakabayashi, T., Hashimoto, A., Nakata, T., Miura, T., Ura, N., Nagao, K., Tsuzuki, M., Wakabayashi, C., & Shimamoto, K. (2006). Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ J, 70, 1451-1456.
81. Kursar, J. D., Nelson, D. L., Wainscott, D., & Baez, M. (1994). Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol. Pharmacol., 46, 227-234.
82. Lairez, O., Cognet, T., Schaak, S., Calise, D., Guilbeau-Frugier, C., Parini, A., & Mialet- Perez, J. (2013). Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice. J Neural Transm (Vienna), 120, 927-935.
83. Lauder, J. M. (1993). Neurotransmitters as growth regulatory signals: role of receptors and second messengers. TINS, 16, 233-240.
84. Lauder, J. M., Wilkie, M. B., Wu, C., & Singh, S. (2000). Expression of 5-HT2A, 5-HT2B and 5-HT2C receptors in the mouse embryo. Int J Dev Neurosci, 18, 653-662.
85. Laugwitz, K.-L., Moretti, A., Lam, J., Gruber, P., Chen, Y., Woodard, S., Lin, L.-Z., Cai, C.- L., Lu, M. M., Reth, M., Platoshyn, O., Yuan, J. X.-J., Evans, S., & Chien, K. R. (2005). Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature, 433, 647-653.
86. Launay, J.-M., Hervé, P., Callebert, J., Mallat, Z., Collet, C., Doly, S., Belmer, A., Diaz, S. L., Hatia, S., Côté, F., Humbert, M., & Maroteaux, L. (2012). Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood, 119, 1772-1780.
87. Launay, J. M., Hervé, P., Peoc'h, K., Tournois, C., Callebert, J., Nebigil, C., Etienne, N., Drouet, L., Humbert, M., Simonneau, G., & Maroteaux, L. (2002). Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med, 8, 1129-1135.
88. Lenke, R. R., & Levy, H. R. (1980). Maternal phenylketonuria and hyperphenylalaninemia: an international survey of the outcome of untreated and treated pregnancies. N Eng J Med, 303, 1202-1208.
89. Lesch, K. P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Muller, C. R., Hamer, D. H., & Murphy, D. L. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274, 1527-1531.
90. Levy, F. O., Qvigstad, E., Krobert, K. A., Skomedal, T., & Osnes, J. B. (2008). Effects of serotonin in failing cardiac ventricle: signalling mechanisms and potential therapeutic implications. Neuropharmacology, 55, 1066-1071.
91. Liang, Y. J., Lai, L. P., Wang, B. W., Juang, S. J., Chang, C. M., Leu, J. G., & Shyu, K. G. (2006). Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-kappaB in cardiomyocytes. Cardiovasc Res, 72, 303- 312.
92. Linder, A. E., Ni, W., Szasz, T., Burnett, R., Diaz, J., Geddes, T. J., Kuhn, D. M., & Watts, S. W. (2008). A serotonergic system in veins: serotonin transporter-independent uptake. J Pharmacol Exp Ther, 325, 714-722.
93. Long, L., MacLean, M. R., Jeffery, T. K., Morecroft, I., Yang, X., Rudarakanchana, N., Southwood, M., James, V., Trembath, R. C., & Morrell, N. W. (2006). Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res, 98, 818-827.
94. Louik, C., Lin, A. E., Werler, M. M., Hernandez-Diaz, S., & Mitchell, A. A. (2007). First- trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med, 356, 2675-2683.
95. Machado, R. D., Koehler, R., Glissmeyer, E., Veal, C., Suntharalingam, J., Kim, M., Carlquist, J., Town, M., Elliott, C. G., Hoeper, M., Fijalkowska, A., Kurzyna, M., Thomson, J. R., Gibbs, S. R., Wilkins, M. R., Seeger, W., Morrell, N. W., Gruenig, E., Trembath, R. C., & Janssen, B. (2006). Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med, 173, 793-797.
96. Machida, T., Ohta, M., Onoguchi, A., Iizuka, K., Sakai, M., Minami, M., & Hirafuji, M. (2011). 5-Hydroxytryptamine induces cyclooxygenase-2 in rat vascular smooth muscle cells: Mechanisms involving Src, PKC and MAPK activation [corrected].
97. Eur J Pharmacol, 656, 19-26.
98. Marzak, H., Ayme-Dietrich, E., Lawson, R., Mokni, W., Combe, R., Becker, J., Fertak, L. E., Champy, M. F., & Monassier, L. (2014). Old spontaneously hypertensive rats gather together typical features of human chronic left-ventricular dysfunction with preserved ejection fraction. J Hypertens, 32, 1307-1316.
99. Mialet-Perez, J., D'Angelo, R., Villeneuve, C., Ordener, C., Negre-Salvayre, A., Parini, A., & Vindis, C. (2012). Serotonin 5-HT2A receptor-mediated hypertrophy is negatively regulated by caveolin-3 in cardiomyoblasts and neonatal cardiomyocytes. J Mol Cell Cardiol, 52, 502-510.
100. Miyazaki, M., Higashi, Y., Goto, C., Chayama, K., Yoshizumi, M., Sanada, H., Orihashi, K., & Sueda, T. (2007). Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol, 49, 221-227.
101. Monassier, L., Laplante, M. A., Ayadi, T., Doly, S., & Maroteaux, L. (2010). Contribution of gene-modified mice and rats to our understanding of the cardiovascular pharmacology of serotonin. Pharmacol Ther, 128, 559-567.
102. Monassier, L., Laplante, M. A., Jaffre, F., Bousquet, P., Maroteaux, L., & de Champlain, J. (2008). Serotonin 5-HT2B receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice. Hypertension, 52, 301-307.
103. Muntasir, H. A., Bhuiyan, M. A., Ishiguro, M., Ozaki, M., & Nagatomo, T. (2006). Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor. J Pharmacol Sci, 102, 189-195.
104. Nebigil, C. G., Choi, D.-S., Dierich, A., Hickel, P., Le Meur, M., Messaddeq, N., Launay, J.- M., & Maroteaux, L. (2000a). Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A, 97, 9508-9513.
105. Nebigil, C. G., Etienne, N., Messaddeq, N., & Maroteaux, L. (2003). Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B-receptor signaling. FASEB J, 17, 1373-1375.
106. Nebigil, C. G., Hickel, P., Messaddeq, N., Vonesch, J.-L., Douchet, M.-P., Monassier, L., György, K., Martz, R., Andriantsitohaina, R., Manivet, P., Launay, J.-M., & Maroteaux, L. (2001). Ablation of serotonin 5-HT2B receptors in mice leads to abnormal cardiac structure and function. Circulation, 103, 2973-2979.
107. Nebigil, C. G., Launay, J.-M., Hickel, P., Tournois, C., & Maroteaux, L. (2000b). 5- Hydroxytryptamine 2B receptor regulates cell-cycle progression: Cross talk with tyrosine kinase pathways. Proc Natl Acad Sci U S A, 97, 2591-2596.
108. Ni, W., Lookingland, K., & Watts, S. W. (2006). Arterial 5-hydroxytryptamine transporter function is impaired in deoxycorticosterone acetate and Nomega-nitro-L-arginine but not spontaneously hypertensive rats. Hypertension, 48, 134-140.
109. Noskova, T., Pivac, N., Nedic, G., Kazantseva, A., Gaysina, D., Faskhutdinova, G., Gareeva, A., Khalilova, Z., Khusnutdinova, E., Kovacic, D. K., Kovacic, Z., Jokic, M., & Seler, D. M. (2008). Ethnic differences in the serotonin transporter polymorphism (5- HTTLPR) in several European populations. Prog Neuropsychopharm, 32, 1735-1739.
110. Ohri, S. K., Schofield, J. B., Hodgson, H., Oakley, C. M., & Keogh, B. E. (1994). Carcinoid heart disease: early failure of an allograft valve replacement. Ann Thorac Surg, 58, 1161-1163.
111. Orton, E. C., Lacerda, C. M. R., & MacLea, H. B. (2012). Signaling pathways in mitral valve degeneration. J Vet Cardiol, 14, 7-17.
112. Pavone, L. M., Spina, A., Lo Muto, R., Santoro, D., Mastellone, V., & Avallone, L. (2008). Heart valve cardiomyocytes of mouse embryos express the serotonin transporter SERT. Biochem Biophys Res Commun, 377, 419-422.
113. Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993). Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation, 87, 1188-1196.
114. Porvasnik, S. L., Germain, S., Embury, J., Gannon, K. S., Jacques, V., Murray, J., Byrne, B. J., Shacham, S., & Al-Mousily, F. (2010). PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther, 334, 364-372.
115. Prante, C., Milting, H., Kassner, A., Farr, M., Ambrosius, M., Schon, S., Seidler, D. G., Banayosy, A. E., Korfer, R., Kuhn, J., Kleesiek, K., & Gotting, C. (2007). Transforming growth factor beta1-regulated xylosyltransferase I activity in human cardiac fibroblasts and its impact for myocardial remodeling. J Biol Chem, 282, 26441-26449.
116. Qvigstad, E., Brattelid, T., Sjaastad, I., Andressen, K. W., Krobert, K. A., Birkeland, J. A., Sejersted, O. M., Kaumann, A. J., Skomedal, T., Osnes, J. B., & Levy, F. O. (2005). Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc Res, 65, 869-878.
117. Rajamannan, N. M., Caplice, N., Anthikad, F., Sebo, T. J., Orszulak, T. A., Edwards, W. D., Tajik, J., & Schwartz, R. S. (2001). Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis, 10, 827-831.
118. Rapport, M. M., Green, A. A., & Page, I. H. (1948a). Crystalline Serotonin. Science, 108, 329-330.
119. Rapport, M. M., Green, A. A., & Page, I. H. (1948b). Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem, 176, 1243-1251.
120. Ren, S., Qian, S., Wang, W., Liu, J., & Liu, P. (2013). Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. Ann Thorac Cardiovasc Surg, 19, 30-34.
121. Rhodes, C. J., Davidson, A., Gibbs, J. S., Wharton, J., & Wilkins, M. R. (2009). Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther, 121, 69-88.
122. Ridker, P. M., Chertow, G. M., Karlson, E. W., Neish, A. S., & Schoen, F. J. (1991). Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. Am Heart J, 121, 1835-1838.
123. Roberts, W. C. (1997). A unique heart disease associated with a unique cancer: carcinoid heart disease. Am J Cardiol, 80, 251-256.
124. Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995). Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation, 92, 790-795.
125. Roth, B. L. (2007). Drugs and valvular heart disease. N Engl J Med, 356, 6-9.
126. Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000). Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 102, 2836-2841.
127. Roux, C., Madani, M., Launay, J.-M., Rey, F., Citadelle, D., Mulliez, N., & Kolf, M. (1995). Serotonin deficiency in phenylketonuria embryopathy. Toxicol. in Vitro, 9, 653-662.
128. Rouzaud-Laborde, C., Delmas, C., Pizzinat, N., Tortosa, F., Garcia, C., Mialet-Perez, J., Payrastre, B., Sié, P., Spreux-Varoquaux, O., Sallerin, B., Carrié, D., Galinier, M., Parini, A., & Lairez, O. (2015). Platelet activation and arterial peripheral serotonin turnover in cardiac remodeling associated to aortic stenosis. American journal of hematology, 90, 15-19.
129. Sauer, W. H., Berlin, J. A., & Kimmel, S. E. (2003). Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation, 108, 32-36.
130. Saugstad, L. F. (1977). Heterozygote advantage for the phenylketonuria allele. Journal of medical genetics, 14, 20-24.
131. Schmuck, K., Ullmer, C., Kalkman, H., Probst, A., & Lübbert, H. (1996). Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci, 8, 959-967.
132. Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003). 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol, 63, 1223-1229.
133. Sharma, S. K., Del Rizzo, D. F., Zahradka, P., Bhangu, S. K., Werner, J. P., Kumamoto, H., Takeda, N., & Dhalla, N. S. (2001). Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. Ann Thorac Surg, 71, 1856-1864; discussion 1865.
134. Shworak, N. W. (2004). Angiogenic modulators in valve development and disease: does valvular disease recapitulate developmental signaling pathways? Curr Opin Cardiol, 19, 140-146.
135. Simões-Pereira, J., Wang, L. M., Kardos, A., & Grossman, A. (2017). Carcinoid syndrome and carcinoid heart disease as manifestations of non-metastatic ovarian neuroendocrine tumour. Acta medica portuguesa, 30, 421-425.
136. Singh, S., Johnson, P. I., Javed, A., Gray, T. S., Lonchyna, V. A., & Wurster, R. D. (1999). Monoamine-and histamine-synthesizing enzymes and neurotransmitters within neurons of adult human cardiac ganglia. Circulation, 99, 411-419.
137. Sole, M. J., Shum, A., & Van Loon, G. R. (1979). Serotonin metabolism in the normal and failing hamster heart. Circ Res, 45, 629-634.
138. Somberg, T. C., & Arora, R. R. (2008). Depression and heart disease: therapeutic implications. Cardiology, 111, 75-81.
139. Strik, J. J., Honig, A., & Maes, M. (2001). Depression and myocardial infarction: relationship between heart and mind. Prog Neuropsychopharm, 25, 879-892.
140. Sun, Y. M., Su, Y., Jin, H. B., Li, J., & Bi, S. (2011). Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress. Int J Cardiol, 147, 383- 387.
141. Takahara, M., Kaneto, H., Katakami, N., Iida, O., Matsuoka, T. A., & Shimomura, I. (2014). Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia. Heart Vessels, 29, 563-567.
142. Takano, S., Hoshino, Y., Li, L., Matsuoka, I., Ono, T., & Kimura, J. (2004). Dual roles of 5- hydroxytryptamine in ischemia-reperfusion injury in isolated rat hearts. J Cardiovasc Pharmacol Ther, 9, 43-50.
143. Takishita, E., Takahashi, A., Harada, N., Yamato, M., Yoshizumi, M., & Nakaya, Y. (2004). Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. J Cardiovasc Pharmacol, 43, 266-270.
144. Tiihonen, J., Lonnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet, 374, 620-627.
145. Ullmer, C., Schmuck, K., Kalkman, H. O., & Lübbert, H. (1995). Expression of serotonin receptor mRNA in blood vessels. FEBS Lett., 370, 215-221.
146. Vialli, M., & Erspamer, V. (1933). Xellule enterochromaffini e cellule basigranulose acidofile nei vertebrati. Z. Zellforsch. Mikrosk. Anat., 19, 743.
147. Vikenes, K., Farstad, M., & Nordrehaug, J. E. (1999). Serotonin is associated with coronary artery disease and cardiac events. Circulation, 100, 483-489.
148. Villalón, C. M., & Centurión, D. (2007). Cardiovascular responses produced by 5- hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn-Schmied Arch Pharmacol, 376, 45-63.
149. Vindis, C., D'Angelo, R., Mucher, E., Negre-Salvayre, A., Parini, A., & Mialet-Perez, J. (2010). Essential role of TRPC1 channels in cardiomyoblasts hypertrophy mediated by 5-HT2A serotonin receptors. Biochem Biophys Res Commun, 391, 979-983.
150. Visconti, R. P., Ebihara, Y., LaRue, A. C., Fleming, P. A., McQuinn, T. C., Masuya, M., Minamiguchi, H., Markwald, R. R., Ogawa, M., & Drake, C. J. (2006). An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ Res, 98, 690-696.
151. Watanabe, T., Pakala, R., Katagiri, T., & Benedict, C. R. (2001). Serotonin potentiates angiotensin II--induced vascular smooth muscle cell proliferation. Atherosclerosis, 159, 269-279.
152. Watts, S. W., Baez, M., & Webb, R. C. (1996). The 5-hydroxytryptamine2B receptor and 5- HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate- salt hypertensive rats. J Pharmacol Exp Ther, 277, 1103-1113.
153. Watts, S. W., & Fink, G. D. (1999). 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Am J Physiol, 276, H944-952.
154. Watts, S. W., Gilbert, L., & Webb, R. C. (1995). 5-Hydroxytryptamine2B receptor mediates contraction in the mesenteric artery of mineralocorticoid hypertensive rats. Hypertension, 26, 1056-1059.
155. Watts, S. W., Morrison, S. F., Davis, R. P., & Barman, S. M. (2012). Serotonin and blood pressure regulation. Pharmacol Rev, 64, 359-388.
156. Watts, S. W., Darios, E. S., Seitz, B. M., & Thompson, J. M. (2015). 5-HT is a potent relaxant in rat superior mesenteric veins. Pharmacol Res Perspect, 3, e00103.
157. Weir, E. K., Obreztchikova, M., & Hong, Z. (2008). Fenfluramine: riddle or Rosetta stone? Eur Respir J, 31, 232-235.
158. Weiss, O. (1896). Über die Wirkungen von Blutserum-Injectionen ins Blut. Archiv für die Gesamte Physiologie des Menschen und der Thiere, LXV, 215-230.
159. West, J. D., Carrier, E. J., Bloodworth, N. C., Schroer, A. K., Chen, P., Ryzhova, L. M., Gladson, S., Shay, S., Hutcheson, J. D., & Merryman, W. D. (2016). Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension. PloS one, 11, e0148657.
160. Whyte, E. M., Pollock, B. G., Wagner, W. R., Mulsant, B. H., Ferrell, R. E., Mazumdar, S., & Reynolds, C. F., 3rd. (2001). Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry, 158, 2074-2076.
161. Wilkinson, L. O., & Dourish, C. T. (1991). Serotonin and animal behavior. In S. J. Peroutka (Ed.), Serotonin receptor subtypes: Basic and clinical aspects (Vol. 15, pp. 147-210). New-York: Wiley-Liss.
162. Xu, J., Jian, B., Chu, R., Lu, Z., Li, Q., Dunlop, J., Rosenzweig-Lipson, S., McGonigle, P., Levy, R. J., & Liang, B. (2002). Serotonin mechanisms in heart valve disease II: the 5- HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol, 161, 2209-2218.
163. Yamada, K., Niki, H., Nagai, H., Nishikawa, M., & Nakagawa, H. (2012). Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT2A receptors in promoting thrombosis in diabetes. J Pharmacol Sci, 119, 243-250.
164. Yan, L., Chen, X., Talati, M., Nunley, B. W., Gladson, S., Blackwell, T., Cogan, J., Austin, E., Wheeler, F., Loyd, J., West, J., & Hamid, R. (2016). Bone marrow-derived cells contribute to pathogenesis of pulmonary arterial hypertension. Am J Resp Crit Care Med, 193, 898-909.
165. Yavarone, M. S., Shuey, D. L., Sadler, T. W., & Lauder, J. M. (1993). Serotonin uptake in the ectoplacental cone and placenta of the mouse. Placenta, 14, 149-161.
166. Yu, Z., Ohba, M., Nakamura, M., Sasano, T., Ono, M., Sugawara, S., & Endo, Y. (2009). Dynamics of platelet mobilisation into lungs in response to 5-hydroxytryptamine (serotonin) in mice. Thromb Haemost, 102, 1251-1258.
167. Zopf, D. A., Neves, L. A. A. d., Nikula, K. J., Huang, J., Senese, P. B., & Gralinski, M. R. (2011). C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol, 670, 195-203.
168. Zuetenhorst, J. M., Bonfrer, J. M., Korse, C. M., Bakker, R., van Tinteren, H., & Taal, B. G. (2003). Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer, 97, 1609-1615.